Literature DB >> 12489154

Porcine N-acetylgalactosamine 6-sulfatase (GALNS) cDNA sequence and expression in developing teeth.

Yasuo Yamakoshi1, Jan C C Hu, Shengxi Liu, Xiaoling Sun, Chuhua Zhang, Shinichiro Oida, Makato Fukae, James P Simmer.   

Abstract

Mucopolysaccharidosis type IVA (Morquio A syndrome, MPS IVA) is a rare, autosomal recessive disorder with a prevalence of 1 in 170,000 live births. It is caused by a deficiency of N-acetylgalactosamine 6-sulfatase (GALNS), a lysosomal hydrolase encoded by a gene on human chromosome 16q24.3. Mucopolysaccharidosis type IVA is the only known MPS that is associated with structural defects in dental enamel. GALNS cleaves the sulfate group from N-acetylgalactosamine 6-sulfate and galactose 6-sulfate, which are specifically found in keratan sulfate and chondroitin 6-sulfate. A pathologic absence of GALNS activity results in the accumulation of these glycosaminoaglycans in the urine and in the lysosomes of tissues that turn them over. There is currently no animal model for MPS IVA. To learn more about how a GALNS deficit could lead to enamel defects, we have cloned and characterized a full-length pig GALNS cDNA. GALNS mRNA was localized in developing teeth by in situ hybridization, Northern blot, and reverse-transcription polymerase chain reaction analyses, while GALNS substrates were localized using immunohistochemistry. We report that secretory ameloblasts were positive for GALNS mRNA, as well as for keratan sulfate and chondroitin 6-sulfate. We conclude that enamel defects associated with the loss of GALNS activity in persons with MPS IVA are likely to result from the pathological accumulation of keratan sulfate and chondroitin 6-sulfate in the lysosomes of secretory stage ameloblasts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12489154     DOI: 10.1080/03008200290001131

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  3 in total

1.  Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study.

Authors:  Renata Quirino de Almeida-Barros; Paula Frassinetti Vasconcelos de Medeiros; Marcella Quirino de Almeida Azevedo; Adriana de Oliveira Lira Ortega; Angela Toshie Araki Yamamoto; Sheyla Kátia Lúcio Dornelas; Patrícia Meira Bento
Journal:  Clin Oral Investig       Date:  2017-03-19       Impact factor: 3.573

Review 2.  Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA.

Authors:  Christian J Hendriksz; Maisoon Al-Jawad; Kenneth I Berger; Sara M Hawley; Rebecca Lawrence; Ciarán Mc Ardle; C Gail Summers; Elizabeth Wright; Elizabeth Braunlin
Journal:  J Inherit Metab Dis       Date:  2012-02-23       Impact factor: 4.982

3.  Matching the Diversity of Sulfated Biomolecules: Creation of a Classification Database for Sulfatases Reflecting Their Substrate Specificity.

Authors:  Tristan Barbeyron; Loraine Brillet-Guéguen; Wilfrid Carré; Cathelène Carrière; Christophe Caron; Mirjam Czjzek; Mark Hoebeke; Gurvan Michel
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.